AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

NovaBay Pharmaceuticals, Inc. Director's Dealing 2021

May 8, 2021

35098_dirs_2021-05-07_3c463de9-7da4-452e-8c27-1648af7a145e.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NovaBay Pharmaceuticals, Inc. (NBY)
CIK: 0001389545
Period of Report: 2021-05-04

Reporting Person: Jones Andrew D. (CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-04	Common Stock	F	77994	$0.7928	Disposed	82006	Direct

Footnotes

F1: Represents payment of tax liability due to vesting of 160,000 time-based restricted stock units (as previously reported on Mr. Jones' Form 3, as filed with the SEC on May 13, 2020).